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The Journal of Immunology
Inositol-Triphosphate 3-Kinase C Mediates Inflammasome
Activation and Treatment Response in Kawasaki Disease
Martin Prince Alphonse,*,† Trang T. Duong,† Chisato Shumitzu,‡ Truong Long Hoang,x
Brian W. McCrindle,{ Alessandra Franco,‡ Ste´phane Schurmans,‖ Dana J. Philpott,*
Martin L. Hibberd,x Jane Burns,‡ Taco W. Kuijpers,# and Rae S. M. Yeung*,†,{
Kawasaki disease (KD) is a multisystem vasculitis that predominantly targets the coronary arteries in children. Phenotypic sim-
ilarities between KD and recurrent fever syndromes point to the potential role of inflammasome activation in KD. Mutations in
NLRP3 are associated with recurrent fever/autoinflammatory syndromes. We show that the KD-associated genetic polymorphism
in inositol-triphosphate 3-kinase C (ITPKC) (rs28493229) has important functional consequences, governing ITPKC protein levels
and thereby intracellular calcium, which in turn regulates NLRP3 expression and production of IL-1b and IL-18. Analysis of
transcript abundance, protein levels, and cellular response profiles from matched, serial biospecimens from a cohort of genotyped
KD subjects points to the critical role of ITPKC in mediating NLRP3 inflammasome activation. Treatment failure in those with
the high-risk ITPKC genotype was associated with the highest basal and stimulated intracellular calcium levels and with increased
cellular production of IL-1b and IL-18 and higher circulating levels of both cytokines. Mechanistic studies using Itpkc-deficient
mice in a disease model support the genomic, cellular, and clinical findings in affected children. Our findings provide the
mechanism behind the observed efficacy of rescue therapy with IL-1 blockade in recalcitrant KD, and we identify that regulation
of calcium mobilization is fundamental to the underlying immunobiology in KD. The Journal of Immunology, 2016, 197: 3481–3489.
K
awasaki disease (KD) is a multisystem vasculitis that
predominantly targets the coronary arteries in infants
and young children (1). KD is characterized by pro-
longed fever and multisystem inflammation with polymorphous
skin rash, oral mucosal changes (red, cracked lips and strawberry
tongue), nonpurulent conjunctival injection, extremity changes
(redness and swelling), and cervical lymphadenopathy. Epidemi-
ological data suggest an environmental trigger with genetic factors
contributing to susceptibility and severity of the disease (2, 3).
Agnostic approaches to interrogate the genome have identified
inositol-triphosphate 3-kinase C (ITPKC) located on chromosome
19q13.2 as a candidate gene (4), implicated as a determinant of
both disease susceptibility and outcome in KD. ITPKC is one of
the three isoenzymes of ITPKs, which phosphorylates inosi-
tol 1,4,5-triphosphate (IP3) to inositol 1,3,4,5-tetraphosphate
(IP4) and acts as a regulator of calcium response to extracellular
signals (5). Additionally, whole-genome expression profile anal-
ysis of acute KD patients has identified the key role of the IL-1b
pathway activation in the inflammatory profile (6). These data,
taken together with phenotypic similarities between KD and re-
current fever syndromes in childhood, point to the potential role
of inflammasome activation in the immunopathogenesis of KD.
Inflammasomes are multiprotein complexes involved in sensing
danger signals in innate immunity, with NLRP3 activation acting
as a key component. Mutations in NLRP3 are associated with
recurrent fever/autoinflammatory syndromes in childhood (7).
Both extracellular and intracellular calcium concentration ([Ca2+]i)
have recently been shown to regulate NLRP3 inflammasome
activation and consequent IL-1b and IL-18 production (8, 9).
Given the role of ITPKC in calcium responses and its association
with KD, we sought to determine whether ITPKC mediates
NLRP3 inflammasome activation in KD.
Using studies of Itpkc-deficient mice (10) in an animal model
of KD, we show that ITPKC controls NLRP3 activation via reg-
ulation of [Ca2+]i mobilization. In children, we show that the
KD-associated genetic polymorphism in ITPKC (rs28493229) has
important functional consequences, directly affecting ITPKC
protein expression and regulating [Ca2+]i mobilization, resulting
in NLRP3 activation and increased production of IL-1b and IL-18,
as demonstrated by gene expression, circulating protein levels,
and functional assays of PBMCs and immortalized cell lines from
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affected children. These biologic data are partnered with evidence
showing resistance to IVIG therapy in those with the ITPKC
polymorphism associated with the highest basal and stimulated
[Ca2+]i levels. Our results demonstrate that ITPKC regulates
NLRP3 activation via [Ca2+]i mobilization, directing production
of IL-1b and IL-18, and that regulation of calcium signaling is
fundamental to the immunopathogenesis of KD.
Materials and Methods
Patient cohorts
Children were included in these studies when they satisfied the American
Heart Association diagnostic criteria for KD (2). Informed consent for
participation was obtained from parents, and informed consent or assent
was obtained from patients as appropriate. The patient cohorts consisted of
185 children with KD from Rady’s Children’s Hospital (San Diego, CA)
and Emma Children’s Hospital, Academic Medical Center (Amsterdam,
the Netherlands). The same set of clinical data and standardized echo-
cardiographic measurements were prospectively collected for all patients.
The median age at diagnosis was 33 mo, 90% of the subjects had complete
KD with median fever duration of 7.1 d, 61% of our cohort were boys, and
all received IVIG therapy. The age-matched febrile controls were diag-
nosed with bacterial or viral infections and were referred for evaluation of
suspected KD but did not satisfy diagnostic criteria. Healthy control
DNA- and EBV-transformed cell lines were obtained from a healthy adult
population-based cohort from The Centre for Applied Genomics at The
Hospital For Sick Children (Toronto, ON, Canada). Participants were
healthy adult volunteers who provided information on demographics and
ethnicity and completed a detailed questionnaire for major diseases, in-
cluding autoimmune, cardiovascular, respiratory, genetic/metabolic, and
allergic diseases. Their respective Institutional Research Ethics Boards
approved all studies.
Clinical and laboratory data
Detailed demographic, clinical, and laboratory data were captured at di-
agnosis (pretreatment) and at 6 mo. Clinical data were collected pro-
spectively using standardized clinical reporting forms, which captured all
key features in the American Heart Association diagnostic criteria and
included standard laboratory markers and standardized echocardiographic
imaging of the heart and coronary arteries. Coronary dimensions were
converted to body surface area–normalized z-scores as per protocol (11).
Biologic sample collection
Peripheral blood samples were collected and processed as per standardized
protocol at each study visit and stored locally at280˚C, then transported to
the central analysis sites for cytokine analysis and cellular assays (The
Hospital For Sick Children) or gene expression microarray (Genome In-
stitute of Singapore, Singapore).
Mice
Four-week-old C57BL/6 mice were purchased from The Jackson Labo-
ratory (Bar Harbor, ME). ITPKC knockout mice were generated by
Schurmans and colleagues (10). Both wild-type C57BL/6 and ITPKC2/2
mice (10) were housed under specific pathogen-free conditions at the
University Health Network (Toronto, ON, Canada). All animal studies
were performed according to guidelines and procedures approved by the
Animal Care Committee at both The Hospital for Sick Children Research
Institute and the University Health Network.
In vivo studies
Four-week-old C57BL/6 or ITPKC2/2 mice were injected with either PBS
alone or Lactobacillus casei cell wall extract (LCWE; 1 mg per mouse)
was administered i.p. as per protocol (12). Animals were sacrificed at 48 h,
after which blood was collected and serum was extracted, aliquoted, and
stored at 280˚C until use. LCWE was prepared as previously described
(13). Coronary arteritis incidence and severity were scored by two inde-
pendent reviewers, who were blinded to the genotypes of the experimental
groups, on a semiquantitative scale as previously reported (12).
Cell cultures
EBV-transformed cell lines from affected children (14) and healthy controls
were obtained and maintained in RPMI 1640 (VWR International, Mis-
sissauga, ON, Canada) supplemented with 10% FBS, 1 mM sodium pyru-
vate, 0.1 mM nonessential amino acids, 50 mM 2-ME, 2 mM L-glutamine,
10 mMHEPES, 100 U/ml penicillin, and 100 mg/ml streptomycin (complete
RPMI; Life Technologies, Burlington, ON, Canada).
Bone marrow–derived macrophages
Bone marrow–derived macrophages (BMDMs) were obtained by differ-
entiating bone marrow progenitors from the tibia and femur of 8- to 12-wk-
old wild-type C57BL/6 or ITPKC2/2 mice in complete RPMI containing
20 ng/ml M-CSF (Sigma-Aldrich, St. Louis, MO) for 7 d. BMDMs were
then replated in 24-well plates at 2.5 3 105 cells/ml (VWR International)
1 d before experimental assays.
Inflammasome activation
EBV-transformed B cells were cultured in complete RPMI 1640 at 23 106
cells/ml in 48-well plates in the presence of absence of either 100 ng/ml
LPS, 5 mM ATP, or LPS plus ATP (Sigma-Aldrich). Following an incu-
bation period of 18 h, supernatants were collected and IL-1b and IL-18
assayed by ELISA according to the manufacturer’s instructions (eBio-
science, San Diego, CA). Cell pellets were collected and stored at 280˚C
until used in Western blotting as described below. In all cases, ATP was
added only during the last 30 min of incubation. Cell pellets were har-
vested for RNA extraction and NLRP3 mRNA expression by quantitative
real-time PCR.
In experiments where PBMCs from affected children were used, the cells
were cultured for 5 h at 2 3 106 cells in 48-well plates in either complete
RPMI alone or complete RPMI containing 400 ng/ml LPS. ATP was added
at a final concentration of 5 mM during the last hour of incubation. Su-
pernatants were then collected and assayed for IL-1b and IL-18 by ELISA.
BMDMs from either wild-type C57BL/6 or ITPKC2/2 mice were
cultured at 2.5 3 105 cells/ml in 24-well plates in complete RPMI alone,
LCWE (0.1 mg/ml), or LPS (1 mg/ml) (Sigma-Aldrich) for 18 h. ATP
(5 mM) (Sigma-Aldrich) was added during the last 45 min of incubation
for activation of inflammasomes. Supernatants and cell lysates were col-
lected and assayed for IL-1b and IL-18 by ELISA and for NLRP3 protein
by Western blotting.
Gene expression microarray
Illumina gene expression microarray platforms were used in this study. The
detailed protocol was as previously published (15). One-color array tech-
nology on the Illumina microarray platform (Illumina, San Diego, CA)
was used to analyze gene expression. In brief, whole blood (2.5 ml) was
collected directly into PAXgene RNA tubes (Qiagen, Sussex, U.K.).
RNA extraction was performed using PAXgene RNA kits (Qiagen).
Biotinylated amplified cRNA was generated by in vitro transcription
technology using an Illumina TotalPrep RNA amplification kit (Ambion,
Austin, TX) according to the manufacturer’s instructions. After purifi-
cation, 2 mg of cRNA was hybridized to an Illumina HumanRef-12 V4
BeadChip (containing probes for more than 47,000 gene transcripts) at
55˚C for 18 h following the manufacturer’s instructions. This was fol-
lowed by washing, blocking, and streptavidin-Cy3 staining steps. Finally,
the chip was scanned with an Illumina BeadArray Reader confocal scanner
and checked using Illumina QC analysis. Background subtracted raw gene
expression intensity data were exported from GenomeStudio and used for
further analysis. Data were quantile normalized using the lumi R package
(http://www.bioconductor.org) before log2 transformation was performed.
Finally, only genes that were detected (detection p value of #0.001) in at
least one sample were used for downstream analysis.
Quantitative real-time PCR analysis
Cells were lysed with TRIzol reagent (Life Technologies), and total RNA
was isolated with a standard chloroform extraction method. cDNA was
synthesized using the GeneAmp RNA PCR kit and murine leukemia virus
reverse transcriptase (Life Technologies). cDNAwas then amplified by real-
time PCR following the manufacturer’s protocol using predesigned
TaqMan primers and a probe set specific for human NLRP3 (assay ID
Hs00918082_m1) and human GAPDH on an ABI Prism 7900 HT system
(Life Technologies). Relative gene expression is presented as the ratio of
gene of interest quantity to GAPDH quantity for each cDNA sample.
Data were analyzed using Sequence Detection Software (v.2.2.2; Life
Technologies). Both the raw and normalized datasets are publically
available at the GEO database (accession no. GSE63881; http://www.ncbi.
nlm.nih.gov/genbank).
Immunoblots
Proteins from lysates of BMDMs and EBV-transformed B cells were
extracted in RIPA buffer (Sigma-Aldrich) containing Halt protease and
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phosphatase inhibitor mixture (Fisher Scientific, Nepean, ON, Canada).
Immunoblots were prepared with Bolt Bis-Tris Plus gel (Life Technologies),
and Western blot analysis was carried out according to standard protocols,
with Abs specific for rabbit polyclonal raised against human NLRP3 (1:6500,
sc-66846; Santa Cruz Biotechnology, Santa Cruz, CA) or rabbit polyclonal
raised against human ITPKC (1:450, PA5-26334; Fisher Scientific). GAPDH
was used as loading control (AM4300; Life Technologies). Relative protein
levels were normalized to GAPDH as determined by densitometry using
ImageJ software (1.8v; National Institutes of Health).
Quantification of secreted cytokines
All ELISAs were carried out as per the manufacturers’ recommendations.
The following ELISAs were used in this study: mouse IL-1b and IL-18 in
cell culture supernatants or serum were measured using mouse IL-1b
Ready-SET-Go! and mouse IL-18 Platinum ELISA kits (eBioscience).
Human IL-1b, IL-18, IL-1R antagonist (IL-1RA), and IL-18 binding protein
(IL-18BP) in plasma of children were measured using the following ELISA
kits: human IL-1b Ready-SET-Go!, human-IL-18 Platinum, human IL-1RA
(eBioscience), and human IL-18BP (Abcam, Toronto, ON, Canada).
Calcium analysis by confocal microscopy
BMDMs were plated on a four-chambered glass dishes (Fisher Scientific)
at 0.1 3 106 cells per chamber. Cells were loaded with Fluo-4 AM (Life
Technologies) in Ca2+-free DMEM media (Life Technologies) supple-
mented with 10% FBS, 1 mM sodium pyruvate, 0.1 mM nonessential
amino acids, 50 mM 2-ME, 2 mM L-glutamine, and 10 mM HEPES
(complete DMEM) and maintained in 37˚C. Live images of untreated cells
were taken at t = 0. Cells were then treated with 1 mM ATP or 1.5 mM
CaCl2 in Ca
2+-free DMEM at t = 0. Cells were imaged for 40 min with
acquisition at 15-s intervals. Ionomycin (1 mM) (Sigma-Aldrich) was
added at the end of 30 min to medium, and cells were imaged for the
remaining time. Images were acquired using an Olympus 1X81 motorized
inverted fluorescence microscope with a Hamamatsu C9100-13 black-
thinned EM-CCD camera and Yokogawa CSU X1 spinning disc confo-
cal imaging system using a 488-nm laser and emission in the range of
500–600 (Carl Zeiss, Toronto, ON, Canada). Images were analyzed using
Volocity software (PerkinElmer, Woodbridge, ON, Canada). Absolute in-
tensity for cells in five independent fields at different time points was
obtained and the average is displayed as the mean fluorescence intensity
(MFI) of all cells in the fields.
Calcium analysis by FACS
EBV-transfected B cells (5–8 3 106 cells) were loaded with Fluo-4 AM
and Fura Red (Life Technologies) loading dyes in Ca2+-free complete
DMEM media and incubated at 37˚C for 35 min. The cells were rested
at room temperature for 20 min before diluting the loaded cells to 3 3
106 cells/ml in Ca2+-free DMEM media supplemented with 10% FBS,
1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 50 mM 2-ME,
2 mM L-glutamine, and 10 mM HEPES. [Ca2+]i mobilization was acquired
for a continuous 10 min using a BD LSR II analyzer (BD Biosciences,
Mississauga, ON, Canada). For blocking IP3R, xestospongin C (XeC)
(Tocris Bioscience, Minneapolis, MN) was added at 3 mM for 15 min prior
to acquisition in the presence or absence of CaCl2 (1 mM). To flux Ca
2+,
ionomycin (1 mM) was added at 1 min during the acquisition. Peak MFI of
Fluo-4 AM per minute is represented over time. Data were analyzed using
FlowJo v9 (Tree Star, Ashland, OR) software.
Functional gene prediction
The GeneMANIA program (http://www.genemania.org) was used with the
following query genes in humans: NLRP3, NLRC4, NLRP12, IL-1b, and
FIGURE 1. Absence of ITPKC alters intracellu-
lar calcium mobilization. BMDMs from C57BL/6
and ITPKC2/2 mice were loaded with Fluo-4 AM
in Ca2+-free media and [Ca2+]i was measured using
spinning disc confocal microscopy. MFI (y-axis) of
Fluo-4 AM for cells in five independent fields
(ROIs) over time (x-axis) is shown for (A) media
alone, (B) 1.5 mM CaCl2, and (C) 1 mM ATP.
Ionomycin (1 mM) was added at 30 min (arrow).
FIGURE 2. ITPKC regulates NLRP3 inflammasome
activation and release of IL-1b and IL-18. (A) BMDMs
from C57BL/6 or ITPKC2/2 were stimulated with
LCWE (1 mg/ml) or LPS (100 ng/ml) and ATP
(5 mM). NLRP3 protein was visualized by immunoblot
analysis, quantified by densitometry, and expressed as
arbitrary units (NLRP3 protein expression normalized to
GAPDH). Western blots are representative of three
separate experiments. (B) Coronary arteritis was induced
by i.p. injection of LCWE as per the protocol in 4- to
6-wk-old C57BL/6 (n = 5) and ITPKC2/2 (n = 5) mice,
together with PBS-negative control injections. Serum
IL-1b was determined by ELISA at 48 h. (C) BMDMs
from C57BL/6 and ITPKC2/2 mice were stimulated
with LCWE (0.1 mg/ml). IL-1b production was deter-
mined by ELISA. Data shown are representative of
three experiments. *p , 0.0001.
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IL-18. The network was analyzed for physical interactions and coexpression
of genes to the query genes. Based on the microarray data, expression of
genes during the acute phase of KD was compared with the convalescent
phase of gene expression and is represented as a network with upregulated
genes (red), downregulated genes (blue), and unaltered genes (black).
Genotyping
For genotype, DNA was extracted as previously described (16) from af-
fected children or healthy controls and PCR was performed for polymor-
phism (rs28493229; Applied Biosystems, C_25932098_10) with 20 ng of
DNA following the manufacturer’s instructions.
Statistical analysis
To compare febrile controls and patients with acute and convalescent KD
(paired data), linear generalized estimating equations were used to adjust for
some repeated measures using statistical analysis software (SAS Institute).
A x2 test was performed between responders and nonresponders to IVIG
treatment. A t test or two-way ANOVA was used as appropriate for
analysis of both in vivo or in vitro experiments in mice and humans.
Results
ITPKC-mediated calcium mobilization controls NLRP3
activation
ITPKC governs phosphorylation of IP3 to IP4, hence controlling
calcium release from the endoplasmic reticulum (17). To determine
the contribution of ITPKC in regulating [Ca2+]i mobilization, we
stimulated BMDMs from Itpkc-deficient and wild-type C57BL/6
control mice and evaluated calcium flux. Baseline levels of [Ca2+]i
were higher in the absence of ITPKC compared with wild-type
controls, and stimulation with ionomycin resulted in a marked
increase in [Ca2+]i quantified using Fluo-4 AM by spinning disc
confocal microscopy (Fig. 1). The addition of CaCl2 to the culture
medium increased basal [Ca2+]i in wild-type BMDMs to match
that of the ITPKC-deficient cells, but not calcium flux upon
stimulation, which remained dramatically higher in the ITPKC
knockout cells. The difference in stimulated calcium flux was even
more dramatic in the presence of ATP, a known calcium mediator
via the PKC pathway and a prototypic second signal in inflam-
masome activation (8) (Fig. 1, Supplemental Videos 1–4), sug-
gesting that ITPKC regulation of [Ca2+]i mobilization is
independent of and additional to that of ATP’s effect on release of
[Ca2+]i. Indeed, BMDMs from Itpkc knockout mice had higher
levels of NLRP3 at baseline (Fig. 2A).
LCWE-induced coronary arteritis in mice is an animal model for
KD. It reflects human KD in its time course, pathology, suscep-
tibility in the young, and response to IVIG therapy (18). Stimu-
lation of mouse BMDMs with LPS plus ATP or with LCWE
resulted in NLRP3 activation and exaggerated release of IL-1b in
in vitro culture in Itpkc-deficient cells compared with those from
C57BL/6 wild-type controls. Similarly, during disease develop-
ment in the animal model, Itpkc knock out mice produced higher
levels of circulating IL-1b compared with wild-type controls
FIGURE 3. Increased circulating IL-1b and IL-18 in the acute phase of KD. (A) Box plots depicting concentrations of IL-1b and IL-18 together with
their respective antagonists IL-1RA and IL-18BP, determined by ELISA, in serial plasma samples from children with KD during the acute (n = 48) and
convalescent (n = 24) phases and in age-matched febrile controls (n = 41). (B) Gene expression profile for IL-1b and its antagonist (IL-1RA) and IL-18 and
its antagonist (IL-18BP) in children with KD (n = 171) during acute and convalescent phases of KD. (C) Gene expression profile for IL-1b cognate re-
ceptors (IL-1R1 and IL-1R2) and IL-18 receptors (IL-18R1 and IL-18RAP) from the same patient cohort. The box plots show the median (thick black line)
within the box (25th and 75th percentiles) whose whiskers represent the 3rd and 97th percentiles. Linear generalized estimating equations were used to
adjust for some repeated measures using statistical analysis software to calculate p values. *p , 0.001.
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(Fig. 2B, 2C), but IL-18 was below detectable limits when mea-
sured by ELISA after stimulation with LCWE alone in vitro or
injected in vivo in the same experiments, respectively. The in-
creased inflammasome activation and IL-1b production also
correlated with increased disease, with LCWE-injected ITPKC-
deficient mice developing more disease with increased incidence
and severity of coronary artery inflammation compared with
wild-type controls (Supplemental Table I).
Elevated circulating levels of IL-1b and IL-18 in acute KD
Children with KD have markedly elevated circulating protein levels
of IL-1b, IL-18, and their respective antagonists, IL-1RA and
IL-18BP, during the acute phase of disease, compared with age-
matched febrile controls (with bacterial or viral infections) and
their own convalescent phase controls (Fig. 3A). This correlates
precisely with increased gene expression for their respective sig-
naling receptor subunits for both the IL-1b and IL-18 pathways
(Fig. 3C). Corresponding increases in mRNA expression for the
ligand/antagonist pair are seen for IL-1b but not for IL-18
(Fig. 3B), in keeping with known regulation of these pathways
with tight regulation of IL-18 expression and signaling (19) and
available noncanonical alternate pathways for IL-1b production (20).
Expression of NLRP3 inflammasome–associated genes during
acute KD
Elevation of IL-1b and IL-18 is a signature associated with acti-
vation of the NLRP3 inflammasome; hence, we explored NLRP3
expression at the mRNA level using gene expression data from serial
samples (whole blood) obtained from children with KD (n = 171).
Upregulation of NLRP3 mRNA was seen during the acute phase
of KD and was accompanied by increased expression of caspase-1
and PYCARD (Fig. 4A), key downstream effectors of inflamma-
some activation responsible for cleavage of pro–IL-1b and pro–
IL-18 into their mature proteins (21). GeneMANIA (http://www.
genemania.org) was used to determine the relationship between
various members of the IL-1b/IL-18 pathway, and it showed
that the increased gene expression profile is specific to NLRP3
inflammasome activation and observed only for molecules im-
mediately downstream of NLRP3 activation and other proteins
implicated in inflammasome activation, including NLRC4 and
NLRP12, but not unrelated NLRPs such as NLRP1, NLRP2, and
NLRP8 (22) (Fig. 4A, 4B).
ITPKC genotype dictates intracellular calcium mobilization
Next we asked whether the ITPKC genotype associated with KD
exhibited phenotypic and functional differences. We genotyped
children with KD at rs28493229, the ITPKC single nucleotide
polymorphism for which the C allele is associated with KD.
EBV-immortalized B cells from affected children were used in
functional assays, where calcium flux was evaluated by flow
cytometry using ratiometrically opposite Ca2+ indicator dyes Fluo-
4 AM and Fura-3 AM in Ca2+-free media. Similar to the ITPKC-
deficient murine cells, basal levels of [Ca2+]i were higher in cells
from children with the CC genotype, which showed a marked
increase in [Ca2+]i upon stimulation with ionomycin compared
with cell lines from KD subjects carrying the GG and GC alleles
(Fig. 5A, 5B). The kinetics of calcium mobilization were also
distinct; upon stimulation, increased [Ca2+]i was sustained in du-
ration in cells from children with the CC genotype compared with
those with GG and GC alleles (Fig. 5A, 5B). The delay in return to
FIGURE 4. Increased expression of NLRP3 inflammasome–associated genes during acute KD. (A) Gene expression profile of inflammasome-associated
genes from serial samples from children with KD (n = 171) during acute and convalescent phases of disease. The box plots show the median (thick black
line) within the box (25th and 75th percentiles) whose whiskers represent the 3rd and 97th percentiles. *p , 0.0001. (B) GeneMANIA functional asso-
ciation gene network for inflammasome-associated genes. The physical interaction and coexpression between genes are expressed as pink and purple lines,
respectively; the thicker the line, the stronger the association. Gene names denoted in red, blue, and black are upregulated, downregulated, or unchanged,
respectively, during acute phase of KD.
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basal levels was not complete at 10 min, the maximum length of
time we used for data capture by flow cytometry. Children with
the CC genotype are infrequent, accounting for only 2.9% in a
cohort of KD children of various ethnicities from the United
States (n = 171), which reflects the 1.5-fold increased frequency
compared with the general population observed in the genetic
discovery analysis (23). Given the small numbers of available
EBV-transformed B cell lines from KD children with the CC
genotype, we sought to confirm the findings in healthy controls
with the disease-associated ITPKC genotype. Control adult EBV-
transformed cell lines were obtained from a healthy subject re-
pository (The Centre for Applied Genomics). From 386 healthy
individuals, seven carried the CC allele (1.8%). Results for cal-
cium flux experiments performed on EBV-infected B cell lines
from these seven individuals were identical to those from the
children with KD, showing the same phenotype, with increased
basal levels of [Ca2+]i together with an exaggerated and prolonged
increase upon stimulation (Supplemental Fig. 1A, 1B). Further-
more, XeC, which specifically inhibits IP3R, reduced [Ca2+]i
mobilization in EBV-infected cells with the ITPKC CC genotype.
The exaggerated [Ca2+]i mobilization phenotype was restored by
addition of extracellular Ca2+ to XeC-treated cells (Fig. 6A).
Results from [Ca2+]i mobilization experiments with XeC-treated
EBV-transformed cells with the ITPKC GC genotype were similar
to those with the GG genotype (Supplemental Fig. 3), confirming
the role of the IP3R in [Ca2+]i mobilization mediated by ITPKC.
ITPKC genotype determines NLRP3 expression
The disease-associated polymorphism is located in an intron be-
tween exons 1 and 2 in the ITPKC gene. The substitution of C for G
at a position eight nucleotides from the splice site is hypothesized
to affect splicing efficiency with lower transcript abundance as-
sociated with the C allele (4). The functional differences seen in
calcium mobilization between the different ITPKC genotypes
paralleled expression of ITPKC protein (Fig. 5C). The association
is striking; that is, those with the disease-associated CC genotype
had decreased ITPKC protein and increased amounts of NLRP3
protein compared with other genotypes at baseline (Fig. 5D).
There was no difference in PYCARD protein expression between
the genotypes (data not shown). The expression of NLRP3 was
tightly associated with that of ITPKC protein, showing an inverse
relationship (Fig. 5C, 5D), which is seen both at the NLRP3
mRNA and protein levels (Fig. 5F). Similar data were seen in our
large cohort of healthy controls (Supplemental Fig. 1C, 1D). The
gene expression profile from children with acute KD shows a trend
toward increased expression of NLRP3 in those with the CC
FIGURE 5. ITPKC genotype dictates
intracellular calcium mobilization and
determines NLRP3 expression. (A) MFI
of Fluo-4 AM (y-axis) acquired by
FACS of EBV-transfected B cells from
various ITPKC genotypes (GG, n = 2;
GC, n = 2; and CC, n = 2) plotted
against time (x-axis). Graph represents
average MFI of four experiments from
each ITPKC genotype. *p , 0.001. (B)
Representative FACS plots of [Ca2+]i
(Fluo-4 AM) over time. (C) Protein ex-
pression of ITPKC protein assayed by
immunoblot of EBV-transfected B cells
from various ITPKC genotypes (GG,
n = 2; GC, n = 2; and CC, n = 2),
quantified by densitometry and expressed
as arbitrary units (ITPKC protein ex-
pression normalized to GAPDH). (D)
NLRP3 protein visualized by immuno-
blot of EBV-transfected B cells from
various ITPKC genotypes (GG, n = 2;
GC, n = 2; and CC, n = 2) quantified by
densitometry and expressed as arbitrary
units (NLRP3 protein expression nor-
malized to GAPDH). Western blots are
representative of three independent ex-
periments. (E) NLRP3 gene expression
from children with KD (GG, n = 111;
GC, n = 44; and CC, n = 5). (F) NLRP3
gene expression from EBV-transfected
B cells (GG, n = 2; GC, n = 2; and CC,
n = 2) as determined by quantitative real-
time PCR.
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genotype, despite the small number of patients (Fig. 5E). Mito-
chondrial superoxide production as a result of increased [Ca2+]i is
thought to mediate activation of the NLRP3 inflammasome (9).
Indeed, there is increased mitochondrial superoxide production in
EBV-transfected B cells from individuals with the ITPKC CC
genotype when compared with those with the GG genotype, when
stimulated with ionomycin. This increase was appropriately re-
versed when ROS production was quenched using superoxide
dismutase (Fig. 6B, 6C).
ITPKC directs production of IL-1b and IL-18 and response to
treatment in children with KD
The functional differences observed in calcium mobilization and
NLRP3 activation for the three different ITPKC genotypes
translated into substantial differences in treatment response. IVIG
is the standard of care for the treatment of acute KD (2). IVIG
nonresponse was defined clinically as persistent or recrudescent
fever 36 h after completion of the IVIG infusion. IVIG nonre-
sponse is correlated with severe disease and poor coronary out-
come. Historically, the IVIG resistance rate is ∼20% regardless of
the cohort studied (5). In our combined cohort of children with
KD, the IVIG resistance rate was 22% in those with the GG or GC
alleles compared with 60% in children with the CC genotype
(Fig. 7A). Coronary outcome, as measured by development of
coronary artery aneurysms and expressed as body surface area–
normalized z-scores (11) for the affected children, did not show a
significant difference between the genotypes, although power was
limited due to the small sample size (Fig. 7B). In the current era of
IVIG treatment, coronary artery aneurysms occur in 5% of ap-
propriately treated children, and thus large numbers of subjects
with each genotype would be required to detect significant dif-
ferences in coronary artery outcome.
Circulating levels of IL-1b and IL-18 measured from plasma of
affected children during the acute phase of KD also showed a
striking correlation with ITPKC genotype; that is, children with
the CC genotype produced the highest concentrations of both
cytokines (Fig. 7C, 7D). Functional testing of PBMCs obtained
from affected children also point to a marked difference in bi-
ologic response between the ITPKC genotypes, with PBMCs
from those with the CC genotype expressing significantly higher
amounts of IL-1b and IL-18 upon stimulation with LPS and ATP,
a prototypic combination of signals for NLRP3 inflammasome
activation (Fig. 7E, 7F) (9). The same was observed in Itpkc-
deficient mice (Fig. 2B, 2C).
Discussion
Prolonged fever in a young child is the cardinal feature of KD. The
syndrome complex associated with KD exemplifies the classic
signs of inflammation, with redness, heat, and swelling affecting
multiple sites. The red skin, eyes, lips, and hands/feet and swollen
lymph nodes are nonspecific findings and common signs of in-
flammation in many febrile illnesses of childhood. Alternatively,
the underlying inflammation in the vasculature, that is, associated
serositis (pleural and pericardial effusions) and other KD-associated
features, including aseptic meningitis, arthritis, gall bladder hydrops,
diarrhea, and abdominal pain, are features commonly seen in re-
current fever syndromes/autoinflammatory disorders. Recurrent
episodes of fever, serositis, arthritis, and cutaneous inflammation
characterize these genetic disorders, which include mutations in
NLRP3 (7). This family of diseases (inflammasomopathies) is part
of a larger family of autoinflammatory diseases characterized by
apparently unprovoked episodes of inflammation (7). KD appears
to bridge the features of acute self-limited fevers in childhood and
inflammasomopathies.
Our data show that the phenotypic similarities between KD and
recurrent fever syndromes are anchored by the common immu-
nobiologic processes associated with inflammasome activation.
Elevated IL-1b and IL-18, the cytokine signature associated with
inflammasome activation, is found in children with KD. In fact,
the distinct difference in circulating levels of these cytokines and
their corresponding antagonists in children with KD compared
with age-matched febrile controls raises the potential of a much-
needed diagnostic biomarker for KD, as KD is defined by a con-
stellation of nonspecific symptoms and does not have a diagnostic
FIGURE 6. ITPKC genotype dictates
intracellular calcium levels and mito-
chondrial superoxide production. (A)
Representative FACS plot showing [Ca2+]i
(Fluo-4 AM) over time acquired for
10 min of EBV-infected B cells from
CC (n = 3) ITPKC genotype treated
with or without XeC in the presence or
absence of CaCl2. (B) MFI (y-axis) for
ionomycin (1 mM)-stimulated EBV-
infected B cells treated with MitoSOX
with from different ITPKC genotypes
GG (gray line) and CC (black line). (C)
Fluorescence intensity (MFI of Mito-
SOX) of EBV-infected B cells of ITPKC
genotypes GG and CC stimulated with
ionomycin alone or with superoxide
dismutase (SOD) and ionomycin (neg-
ative control). Graphs represent four
independent experiments from different
EBV-infected B cell lines. *p , 0.001.
The Journal of Immunology 3487










test. One of the challenges to treating children with KD is early
diagnosis, specifically distinguishing them from children with
fever due to infections and other causes. Delays in patient iden-
tification and treatment lead to poor coronary outcome (24). Many
attempts have been made to identify clinical or biologic markers
for KD but none has proven useful, as many febrile conditions in
childhood, especially those associated with infections, share
similar clinical and laboratory findings, including proinflammatory
cytokines such as TNF-a and IL-2 (25). We have identified po-
tential candidate biomarkers, with circulating levels of IL-1b and
IL-18 and their respective antagonists being significantly different
between children with acute KD and age-matched children with
prolonged fever but not KD (Fig. 3A). Of practical importance is
the stability of potential biomarkers. The IL-18 ligand (26) and both
antagonists, IL-1RA (27) and IL-18BP (28), are stable and not
subject to rapid degradation or special handling, and thus imple-
mentation and incorporation into standard clinical laboratory
testing has minimal obstacles. Further human studies are needed
to specifically address these intriguing possibilities.
We show that ITPKC regulates NLRP3 activation via [Ca2+]i
mobilization, directly modulating the expression of NLRP3 and
subsequent production of IL-1b and IL-18. In humans, the ITPKC
CC genotype, which is implicated as a determinant of KD sus-
ceptibility and outcome (4, 17), is associated with highest basal
and stimulated [Ca2+]i levels, increased mitochondrial superoxide
production, highest levels of NLRP3 protein, greatest production
of IL-1b and IL-18 from their PBMCs and EBV-transformed cell
lines, and highest circulating levels of IL-1b and IL-18 during
acute KD. Associations of IL-18 levels and genetic polymor-
phisms with risks and outcomes in KD have been reported in KD
patients (29, 30). The ITPKC CC genotype is associated with
failure of IVIG therapy. Beyond the potential role of inflamma-
some activation and the predictive role of these cytokines for IVIG
treatment resistance are the clinical implications of IL-1 blockade
in children with recalcitrant disease, a practical reality given the
availability of multiple different formulations of IL-1b blocking
agents available today. Aneurysm formation in the LCWE mouse
model of KD has recently been shown to be mediated by both
IL-1a and IL-1b and is successfully ameliorated by treatment
with anakinra (human IL-1RA) (31), which is in accord with
clinical observations of treatment success with IL-1 blockade in
children with recalcitrant KD (32).
The following disease model (Supplemental Fig. 2) illustrates
the immunobiology highlighted by our results. An environmental/
infectious trigger (33) serves as an initiating danger signal in KD,
leading to activation of the innate immune system and maturation
of APCs into professional APCs. Genetically predisposed indi-
viduals (ITPKC CC genotype) have decreased amounts of ITPKC
FIGURE 7. ITPKC genotype regulates
production of IL-1b and IL-18 and influ-
ences treatment response in children with
KD. (A) Children with KD (GG, n = 101;
GC, n = 36; and CC, n = 10) response to
IVIG treatment in the cohort are represented
as percentage of nonresponders. *p = 0.016;
x2 = 8.1725. (B) Maximum coronary artery
dimensions expressed as body surface area
normalized z-scores from children with KD
(GG, n = 101; GC, n = 36; and CC, n = 10).
Box plots show the median (thick black line)
within the box (25th and 75th percentiles)
whose whiskers represent the 3rd and 97th
percentiles. (C) IL-1b and (D) IL-18 plasma
concentrations during the acute phase of KD
(GG, n = 2; GC, n = 2; and CC, n = 2) as
determined by ELISA. (E) IL-1b and (F) IL-
18 production by PBMCs from affected
children. PBMCs from GG (n = 3) and CC
(n = 5) were stimulated with LPS and ATP.
*p , 0.0001.
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protein that is correlated to their increased risk of disease. De-
creased ITPKC results in reduced phosphorylation/conversion of
IP3 to IP4, thus increasing cytoplasmic IP3 levels. More IP3 leads to
increased IP3 binding to IP3R on the endoplasmic reticulum, re-
leasing [Ca2+]i. Increased [Ca
2+]i increases NLRP3 expression and
inflammasome activation, leading to increased production of active
IL-1b and IL-18 and recalcitrant disease and treatment failure.
In summary, our data show that ITPKC influences NLRP3 ac-
tivation via control of [Ca2+]i mobilization, directing production of
IL-1b and IL-18, pointing to the key role of calcium mobilization
in the immunopathogenesis of KD. ITPKC protein levels and
thereby [Ca2+]i, influence production of mitochondrial superoxide,
leading to alteration in NLRP3 activation. Analysis of transcript
abundance, protein levels, and cellular response profiles from
matched, serial biospecimens from a large cohort of genotyped
KD subjects points to the critical role of ITPKC in mediating
NLRP3 inflammasome activation in KD. Poor treatment response
in those with the ITPKC CC genotype was associated with the
highest basal and stimulated [Ca2+]i levels and with increased cel-
lular production of IL-1b and IL-18 and higher circulating levels of
both cytokines during the acute phase of KD. Mechanistic studies
using Itpkc-deficient mice in an animal model of KD support the
genomic, cellular, and clinical findings in affected children. Our
findings provide the mechanism behind the observed efficacy of
rescue therapy with IL-1 blockade in children with recalcitrant KD
(32). Identifying biologic determinants of disease risk and treatment
response in KD has important implications for biomarker devel-
opment for improved diagnosis and risk stratification.
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Figure S1: ITPKC genotype dictates intracellular calcium levels and NLRP3 protein 
expression in EBV infected B-cells. (a) Mean fluorescence Intensity (MFI) of Fluo-4AM 
(Y-axis) acquired by FACS of EBV immortalized B-cells from three different ITPKC geno-
types [GG (n=6), GC (n=5) and CC (n=7)] plotted against time (X-axis) from healthy controls. 
Graph represents average MFI of 2 experiments from each ITPKC genotypes. (b) Representa-
tive FACS plot showing [Ca2+]i  (Fluo-4AM) over time acquired for 10min for each ITPKC 
genotype. (c) NLRP3 protein expressed from EBV immortalized B-cells from GG (n=4) and 
CC (n=7) was visualized by Immunoblot analysis, (d) quantified by densitometry and 
expressed as arbitrary units (NLRP3 protein expression normalized to GAPDH). Western blots 
are representative of 3 independent experiments.
Figure S2. ITPKC regulates NLRP3 inflammasome activation. NLRP3 inflammasome activation is a two-step process 
with priming and an activation signal. Signal one triggers a pattern recognition receptor on APCs such as Toll like receptors 
(TLRs) to increase pro-IL-1β and pro-IL-18 via the NF-kB pathway. Signal two mediates the assembly and activation of the 
inflammasome, a large molecular platform composed of an NLR protein (such as NLRP3), the adaptor ASC and 
proinflammatory caspases (such as caspase 1). Activation of Caspase 1 cleaves pro-IL-1β and pro-IL-18 into their respective 
active cytokines.  The following steps illustrate the contribution of ITPKC to the disease model: 1. ITPKC regulates 
phosphorylation of IP3 to IP4. Decreased ITPKC (knockout mice or humans with CC genotype) results in increased IP3, 
which binds to IP3R 2. Releasing of intracellular calcium [Ca2+]i from the endoplasmic reticulum (ER). 3. Increased [Ca2+]i 











Figure S3. ITPKC GG and GC genotype [Ca2+]
i
flux can be inhibited by blocking IP3R.
Representative FACS plot showing [Ca2+]
i
(Fluo-4AM) over time acquired for 10min of EBV



















Table S1. Absence of ITPKC increases inflammation in LCWE-induced coronary arteritis
animal model of KD. Incidence of inflammation 28 days after disease induction is presented as
number of mice with histological evidence of inflammation over total number of mice injected.
Disease severity score was determined as previously reported (12). Both disease incidence and
severity were significantly increased in ITPKC-/- mice a (p = 0.0112) and b (p<0.001)
respectively.
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1 
Movies S1-S4. Deficiency of ITPKC leads to increased intracellular calcium at baseline 1 
and with stimulation compared to wild-type controls. (a) BMDMs from C57BL/6 were 2 
loaded with Fluo-4AM in Calcium free media and [Ca2+]i was measured live using time-lapse 3 
confocal spinning disc microscopy. Cells were imaged for 40 min with acquisition at 15 sec 4 
intervals. Cells were treated either with 1mM ATP or 1.5µM CaCl2. Ionomycin (1µM) was 5 
added at the end of 30 min. (S1) C57BL/6 – ATP and Ionomycin.  (S2) ITPKC-/- - ATP and 6 
Ionomycin (S3) C57BL/6 – CaCl2 and Ionomycin (S4) ITPKC-/- - CaCl2 and Ionomycin. 7 
